MARKET reflected a collective growth of 11 per cent for the month while companies in the 11-20 and 2130 bracket grew slower at 8 per cent and 7 per cent respectively. Five of the top 10 companies grew faster than the market. Lupin with 17 per cent growth was the fastest growing company in the top 10 for the month. Among the 11-20 companies, DRL (6 per cent), Sanofi (6 per cent) and Emcure (6 per cent) reflected single digit growth while Pfizer reflected de-growth to the tune of -6 per cent for the month on account of discontinuation of Corex. Domestic companies continued to dominate the market with a 78 per cent share in March 2017 and grew faster than the market with a growth of 10.7per cent while MNCs reflected a 6.5 per cent growth for the month. The largest MNC, Abbott grew slower than the market for the month with 8.59per cent growth while
TABLE 1: PHARMA MARKET SIZE IN MILLION $ BY COUNTRY All values in Million USD
February Month
Month Growth %
MAT February
MAT growth %
Global pharma Mkt
72322
-9.9
1061266
4.3
US
34198
1.9
450721
4.1
Japan
5811
-11.5
79011
6.1
China
4311
-40.52
70148
-3.6
Germany
3134
-5.6
40629
4
Venezuela
2884
129.7
24567
89.3
Brazil
1829
35.6
22540
18.2
UK
1728
-14.9
23304
-9.6
France
1601
-41
32196
-0.8
Canada
1501
2.1
19479
1.8
India
1232
4.9
15456
5.8
Australia
966
15.1
13352
22.8
Italy
946
-60.8
27260
-0.6
Russia
886
4.5
12637
4.9
Spain
814
-54
20057
-2
GSK reflected a growth faster than the market for the first time since July 2016. Pfizer reflected de-growth for the fourth month in a row. Acute therapies remained the strongest pillar of IPM with a 64 per cent contribution to the total market. However, chronic therapies grew 1.3 times the market at 13.2 per cent vis-à-vis a market growth of 9.7 per cent while acute therapies reflected a low growth of 7.9 per cent for the month. Cardiac continued to be the largest therapy area for the month, clocking a revenue of ` 1122 crores. Atorvastatin was the largest molecule in the cardiac space. Though it reflected a value de-growth to the tune of -14per cent the molecule witnessed a volume growth of 6 per cent for the month. Telmisartan which was affected by the NLEM last year reflected a value de-growth (-7.6 per cent) however, robust volume growth was recorded for the
The Standard of Comparison
Pharmaceutical Grade Crystalline, Spray Dried, Anhydrous, and Inhalation Lactose • For more than 70 years, we have delivered the industry's most extensive Lactose portfolio
www.SheffieldBioScience.com
• The original patent for Anhydrous Direct Tabletting (DT) Lactose • Batch to Batch Consistency • Global technical service, regulatory and application expertise to ensure regional and global market compliance
16
EXPRESS PHARMA
May 1-15, 2017
Registered Office Address: 17th Floor, Nirmal Building, Nariman Point, Mumbai - 400021 Corporate Identification Number: U15400MH2010PTC202946 Tel.: +91 22 27815003, Fax Number ; (022- 27815989) Email: Kerry-India.Info@kerry.com